Stryker Co. (NYSE:SYK) – Investment analysts at Northcoast Research cut their Q1 2019 EPS estimates for shares of Stryker in a research report issued on Wednesday. Northcoast Research analyst D. Keiser now anticipates that the medical technology company will earn $1.76 per share for the quarter, down from their prior estimate of $1.77. Northcoast Research also issued estimates for Stryker’s Q2 2019 earnings at $1.89 EPS.
Several other equities analysts have also commented on the stock. JPMorgan Chase & Co. raised shares of Stryker from a “neutral” rating to an “overweight” rating in a report on Tuesday, January 2nd. Zacks Investment Research lowered shares of Stryker from a “hold” rating to a “sell” rating in a report on Saturday, January 20th. BMO Capital Markets raised shares of Stryker to a “market perform” rating and set a $163.00 price target for the company in a research report on Tuesday, December 12th. Cantor Fitzgerald reissued a “neutral” rating and set a $163.00 price target on shares of Stryker in a research report on Friday, January 5th. Finally, SunTrust Banks reissued a “buy” rating and set a $161.00 price target on shares of Stryker in a research report on Friday, November 17th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and sixteen have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $164.76.
Stryker (NYSE:SYK) last released its earnings results on Tuesday, January 30th. The medical technology company reported $1.96 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.95 by $0.01. Stryker had a net margin of 8.20% and a return on equity of 24.56%. The company had revenue of $3.47 billion for the quarter, compared to analyst estimates of $3.42 billion. During the same quarter last year, the firm earned $1.78 EPS. The firm’s quarterly revenue was up 9.9% compared to the same quarter last year.
The business also recently announced a quarterly dividend, which will be paid on Monday, April 30th. Stockholders of record on Thursday, March 29th will be given a $0.47 dividend. The ex-dividend date of this dividend is Wednesday, March 28th. This represents a $1.88 annualized dividend and a dividend yield of 1.12%. Stryker’s dividend payout ratio is 70.15%.
In other news, Director Howard E. Cox, Jr. sold 7,400 shares of the firm’s stock in a transaction dated Friday, February 2nd. The shares were sold at an average price of $164.09, for a total value of $1,214,266.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Yin C. Becker sold 23,221 shares of the firm’s stock in a transaction dated Friday, March 9th. The stock was sold at an average price of $165.96, for a total transaction of $3,853,757.16. Following the completion of the sale, the vice president now directly owns 10,499 shares of the company’s stock, valued at $1,742,414.04. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 43,611 shares of company stock valued at $7,178,719. Corporate insiders own 7.40% of the company’s stock.
Large investors have recently bought and sold shares of the company. Truewealth LLC purchased a new position in Stryker during the 4th quarter valued at about $110,000. Sawyer & Company Inc purchased a new position in Stryker during the 4th quarter valued at about $125,000. Sit Investment Associates Inc. lifted its position in Stryker by 114.3% during the 4th quarter. Sit Investment Associates Inc. now owns 825 shares of the medical technology company’s stock valued at $128,000 after acquiring an additional 440 shares during the period. Virtue Capital Management LLC purchased a new position in Stryker during the 4th quarter valued at about $133,000. Finally, Oak Point Wealth Management purchased a new position in Stryker during the 4th quarter valued at about $145,000. 75.71% of the stock is owned by hedge funds and other institutional investors.
Stryker Company Profile
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.